8-K: Denali Capital Secures $20M PIPE for Semnur Merger

Denali Capital Acquisition Corp. announced a $20 million private investment in public equity (PIPE) financing to support its merger with Semnur Pharmaceuticals, Inc.

Summary

• Denali Capital Acquisition Corp. (Denali) entered a Securities Purchase Agreement on August 20, 2025, with Semnur Pharmaceuticals, Inc. (Semnur) and a Purchaser (JW Capital Securities Limited).
• The Purchaser agreed to buy 1,250,000 shares of common stock of the combined company (New Semnur) at $16.00 per share, totaling $20,000,000.
• This PIPE financing is in connection with the previously announced Business Combination (merger) between Denali and Semnur, as per the Merger Agreement dated August 30, 2024, and amended on April 16, 2025, and July 22, 2025.
• The closing of the PIPE Financing is contingent on customary conditions and is expected to occur immediately following the consummation of the Business Combination.
• Semnur will deposit 12,000,000 shares of New Semnur common stock, beneficially owned by its parent company, Scilex Holding Company, into an escrow account. This deposit will occur no earlier than the PIPE closing and no later than 20 business days after the Business Combination closing.
• The PIPE Shares are being issued in an unregistered sale, relying on exemptions from registration under the Securities Act of 1933, with the Purchaser confirming accredited investor status.

Sentiment

Score: 7

Explanation: The filing announces a significant PIPE financing that provides crucial capital for the impending business combination, indicating progress towards the merger. The escrow share arrangement also adds a layer of commitment. While standard risks are noted, the successful securing of this financing is a positive step for the transaction's completion.

Positives

• Secured $20,000,000 in PIPE financing, providing crucial capital for the combined entity.
• The financing supports the completion of the Business Combination with Semnur Pharmaceuticals, Inc., indicating progress towards the merger.
• The agreement includes a provision for 12,000,000 shares of New Semnur common stock from Semnur's parent company to be held in escrow, potentially aligning interests and providing stability.
• The Registration Statement on Form S-4 for the Business Combination was declared effective on August 12, 2025, and the definitive proxy statement/prospectus was filed and mailed on August 13, 2025, indicating significant progress towards the merger.

Negatives

• The PIPE shares are restricted securities and subject to transfer restrictions, limiting immediate liquidity for the purchaser.
• The Purchase Agreement may be terminated if the PIPE Financing closing has not occurred by December 31, 2025, introducing a deadline risk.
• The filing includes standard forward-looking statements warning of various risks associated with the Business Combination, such as the inability to consummate the merger, failure to realize anticipated benefits, and potential disruptions.

Risks

• General economic, political, and business conditions could impact the transaction.
• Inability of the parties to consummate the Business Combination or occurrence of events leading to termination of the Merger Agreement.
• Outcome of any legal proceedings that may be instituted against the parties following the announcement of the Business Combination.
• Receipt of an unsolicited offer from another party for an alternative business transaction that could interfere with the Business Combination.
• Risk that stockholder approval for the transaction is not obtained from Semnur or Denali shareholders.
• Failure to realize the anticipated benefits of the Business Combination, including delays in consummation or difficulties in integrating the businesses.
• Disruption to current plans and operations as a result of the announcement and consummation of the Business Combination.
• Ability of the combined company to grow, manage growth profitably, and retain key employees.
• Amount of redemption requests made by Denali's shareholders.
• Inability to obtain or maintain the listing of the post-acquisition company's securities on Nasdaq or OTC Markets following the Business Combination.
• Costs related to the Business Combination.

Future Outlook

The PIPE financing is expected to close immediately following the consummation of the Business Combination between Denali and Semnur. Semnur's parent company, Scilex Holding Company, will deposit 12,000,000 shares of New Semnur common stock into an escrow account within 20 business days after the Business Combination closing. The overall Business Combination is progressing, with the Form S-4 registration statement declared effective and proxy materials mailed.

Industry Context

This transaction is a Private Investment in Public Equity (PIPE) financing, a common mechanism used by Special Purpose Acquisition Companies (SPACs) like Denali to raise additional capital and provide certainty of funding for their de-SPAC transactions (business combinations). Semnur Pharmaceuticals, Inc. is a pharmaceutical company, and the merger with Denali aims to bring it to the public market. The escrow share arrangement is a notable feature, potentially signaling long-term commitment from Semnur's parent.

Legal Proceedings

• The 'Forward-Looking Statements' section mentions a risk of 'the outcome of any legal proceedings that may be instituted against the parties following the announcement of the Business Combination.'
• Semnur represents that there is no action, suit, proceeding, inquiry or investigation pending or, to its knowledge, threatened against or affecting Semnur, the New Semnur Common Stock or any of Semnur's officers or directors in their capacities as such.
• Denali represents that there is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to its knowledge, threatened against or affecting Denali or any of its properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority which adversely affects or challenges the legality, validity or enforceability of any of the Denali Transaction Documents or the Common Shares or would, if there were an unfavorable decision, have or reasonably be expected to result in a Denali Material Adverse Effect.
• Neither Denali nor any director or officer thereof is or has been the subject of any action involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty.
• There has not been, and to Denali's knowledge, there is not pending or contemplated, any investigation by the SEC involving Denali or any current or former director or officer of Denali.
• The SEC has not issued any stop order or other order suspending the effectiveness of any registration statement filed by Denali under the 1934 Act or the 1933 Act.

Related Party Transactions

• Semnur's parent company, Scilex Holding Company, will deposit 12,000,000 shares of New Semnur common stock into an escrow account.
• The filing states 'There are no material relationships between the Company or its affiliates and the Purchaser, other than in respect of the Purchase Agreement.'
• Semnur represents that, except as disclosed in the Form S-4, none of its officers, directors or employees is presently a party to any transaction with Semnur (other than for ordinary course services as employees, officers or directors).
• Denali represents that, except as set forth in the SEC Documents, none of its officers or directors and, to its knowledge, none of its employees is presently a party to any transaction with Denali (other than for services as employees, officers and directors).

Stakeholder Impact

• **Shareholders (Denali)**: Will vote on the Business Combination. The PIPE financing provides additional capital, potentially increasing the likelihood of merger completion and the value of the combined entity. However, the issuance of new shares will dilute existing shareholders.
• **Shareholders (Semnur/Scilex Holding Company)**: Scilex Holding Company, as the parent, will have 12,000,000 shares of New Semnur common stock placed in escrow, indicating a long-term commitment but also a restriction on immediate liquidity for those shares.
• **Purchaser (JW Capital Securities Limited)**: Acquires 1,250,000 shares of New Semnur at $16.00 per share, becoming a significant investor in the combined entity, subject to transfer restrictions.
• **Employees (Semnur/Denali)**: The successful merger and financing could provide stability and growth opportunities for employees of the combined company.
• **Management (Semnur/Denali)**: The transaction's completion is a key strategic milestone for both management teams.

Next Steps

• Consummation of the Business Combination between Denali Capital Acquisition Corp. and Semnur Pharmaceuticals, Inc.
• Closing of the PIPE Financing immediately following the Business Combination.
• Deposit of 12,000,000 shares of New Semnur common stock into an escrow account by Semnur's parent company within 20 business days following the Business Combination closing.
• Shareholders of Denali to vote on the Business Combination at an extraordinary general meeting.

Key Dates

Recommendation

The filing details a crucial PIPE financing that significantly de-risks the completion of the Business Combination between Denali Capital Acquisition Corp. and Semnur Pharmaceuticals, Inc. The $20 million capital injection and the escrow of 12 million shares from Semnur's parent company are positive indicators for the merger's success and the stability of the future combined entity. However, without specific financial projections for the combined company or a current market price for Denali's shares to assess the $16.00 PIPE price, a 'hold' recommendation is prudent. Investors should await the full consummation of the merger and further disclosures on the combined entity's operational and financial outlook before making more aggressive investment decisions.

Keywords

Denali Capital Acquisition Corp, Semnur Pharmaceuticals, PIPE financing, Business Combination, Merger Agreement, SEC filing, Form 8-K, private equity, SPAC, pharmaceuticals, Scilex Holding Company, unregistered securities, accredited investor